NUTEX HEALTH INC (NUTX)
Health Care · Micro-hospital operations and population health management · NASDAQ
Nutex Health operates a network of physician-led micro-hospitals and specialty facilities combined with value-based population health management through IPAs to deliver efficient, high-margin acute and primary care in underserved markets.
What NUTEX HEALTH INC does
Nutex Health is a physician-led healthcare services company operating a network of 26 micro-hospitals, specialty hospitals, and hospital outpatient departments across 12 states, while also managing population health through independent physician associations and managed care networks. The hospital division provides comprehensive 24/7 care including emergency, inpatient, and behavioral health services with onsite ancillary services like imaging, labs, and pharmacies. The population health management division operates IPAs that enroll patients and contract with insurers on capitated and value-based reimbursement models, employing 944 FTE staff and contracting with over 3,600 physicians and specialists.
Themes: Micro-hospital / specialty hospital operations, Population health management and capitated care, Value-based healthcare and risk-bearing provider networks, Independent physician associations (IPAs), Emergency and acute care services, Healthcare operations and consolidation
Fundamentals
- Price$185.84 as of 2026-08-21 close
- Market cap$1.3B as of 2026-08-21
- 1-year return+93.2% 2025-08-21 close $96.18 → 2026-08-21 close $185.84
- P/E13.50 as of 2026-08-24
- Net margin+10.9% as of 2026-08-24
- Gross margin+47.5% as of 2026-08-24
- ROE+31.4% as of 2026-08-24
- Debt / equity0.92 as of 2026-08-24
- Revenue growth (YoY)+41.0% as of 2026-08-24
- Revenue CAGR (3y)+58.6% SEC XBRL
- Beta0.58 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +6.3%; pays a dividend.
How NUTX compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- indicated dividend yieldtop 10% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How NUTEX HEALTH INC looks technically
NUTEX HEALTH INC (NUTX) is trading 35.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 46 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 10 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 35.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +35.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $166.18 | $166.18 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $137.51 | $137.51 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 140.25. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 46 trading days ago — a "golden cross", a bullish long-term signal | 46 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control | 34.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 58.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($150.07 to $200.00) — its "stochastic" reading is 72 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 71.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $204.00 | $204.00 |
|---|---|---|
| From the 52-week high | it is 8.9% below its 52-week high (its highest price of the past year) | -8.9% |
| Above the 52-week low | it is 140.7% above its 52-week low (its lowest price of the past year) | +140.7% |
| Below the 52-week high | it is 8.9% below its highest point of the past year | 8.9% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $7920.00 (set on 2022-04-04) | $7920.00 |
| Given back of the 52-week move | over the past year its closes ranged ($80.92 to $197.51), and it has given back only a small part of its rise from last year’s low — 10% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $121.73 to $125.46. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 10.0% |
| From the all-time high | it is 97.7% below its all-time high | -97.7% |
| Nearest price level | it is trading 3.7% below a resistance level at $192.69 — a price it turned at three times since 2025-12-12, most recently on 2026-01-09. Since 2024-08-21 it has 9 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.7% |
| All-time low | its lowest closing price on record is $4.16 (set on 2024-07-10) | $4.16 |
| Above the all-time low | it is 4367.3% above its all-time low | +4,367% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $11.60 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $11.60 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $131.80 and $205.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $131.80 – $168.40 – $205.01 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 4.2 daily ranges above its 200-day average price (35.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.81× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 3.6% since the prior reading | +3.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | today it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 8.4% above the previous close 10 sessions ago and has not traded back through the level it left behind at 151.93 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +8.4% |
| Gap filled | a 2.7% gap up opened on 2026-07-21 has been "filled" 22 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 22 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -2.51% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 8.1 percentage points (the stock gained 10.4% while the market gained 2.3%) | +8.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 53.2 percentage points (the stock gained 56.3% while the market gained 3.1%) | +53.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 72.8 percentage points (the stock gained 83.9% while the market gained 11.1%) | +72.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 72.7 percentage points (the stock gained 93.2% while the market gained 20.5%) | +72.7% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 10.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +6.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 40% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $132.44 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +40.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $179.34 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +3.6% |
Price levels it has turned at before
NUTX last closed at $185.84 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $192.69 | Resistance | 3.7% above the last close | turned there three times · 2025-12-12 to 2026-01-09 |
| $157.07 | Support | 15.5% below the last close | turned there twice · 2025-11-20 to 2025-12-17 |
| $140.18 | Support | 24.6% below the last close | turned there four times · 2025-07-09 to 2026-07-29 |
| $136.91 | Support | 26.3% below the last close | turned there twice · 2025-05-06 to 2025-06-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $140.25.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $228.44 and $282.94 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $140.25.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Printed a bearish engulfing pair · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.20 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$276.00 range $200.00 – $310.00; median $290.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Operational dependency on out-of-network reimbursement and patient out-of-pocket payments; transition to direct commercial payer contracts may face resistance or lower rates than currently realized.","Concentration of facility ownership and control among Chairman/CEO and related Physician LLCs and Real Estate Entities creates related-party transaction risk and potential conflicts of interest.","De novo hospital development pipeline (nine facilities under development) requires significant capital and carries execution and market adoption risks with no guarantee of timely profitability."]
What changed in the latest 10-Q
AI-assisted comparison of NUTX's 10-Q filed 2026-04-30 against the prior one filed 2025-11-19.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-04-30) adds: 'as well as non-emergency services at in-network facilities, and air ambulance services' to NSA description
- Newer filing (2026-04-30) adds: 'subject to federal and state regulations' in CIDRE eligibility determination bullet
- Newer filing (2026-04-30) adds detailed explanation of CIDRE selection process: 'the provider and insurer each submit a final offer, and the CIDRE selects one party's offer as the award after reviewing and evaluating all statutorily required information submitted by both parties' as separate bullet point
- Newer filing (2026-04-30) includes hospital count of 27 facilities in 12 states versus 24 facilities in 11 states (older filing)
- Newer filing (2026-04-30) states approximately 1,005 full-time employees as of March 31, 2026 versus 880 employees at September 30, 2025 (older filing)
- Newer filing (2026-04-30) states 'contracted with over 280 doctors' versus 'contracted 255 doctors' (older filing)
- Newer filing (2026-04-30) states 'partnered with over 3,600 physicians' versus 'over 2,100 physicians' (older filing)
- Newer filing (2026-04-30) provides insurance coverage allocation table for three months ended March 31, 2026 and 2025 only
- Removed:
- Older filing (2025-11-19) includes 'Explanatory Note' section on April 1, 2022 Merger between Nutex Health Holdco LLC and Clinigence Holdings, Inc.; this section is removed in newer filing
- Older filing (2025-11-19) describes hospital division as including 'our healthcare billing and collections organization'; this phrase is removed in newer filing
- Older filing (2025-11-19) refers to 'Real Estate Entities'; newer filing (2026-04-30) uses 'real estate division' and 'Real Estate VIEs' terminology
- Older filing (2025-11-19) states 'The Company has no direct or indirect ownership interest in the Physician LLCs or Real Estate Entities, so 100% of the equity for these entities is shown as noncontrolling interest'; this statement is not present in newer filing
- Older filing (2025-11-19) identifies VIE as 'AHISP, IPA'; newer filing (2026-04-30) identifies it as 'Atlas Healthcare Physicians (Atlas, formerly known as Associated Hispanic Physicians of So. California)'
- Older filing (2025-11-19) provides nine-month comparison table for insurance coverage allocation; newer filing provides only three-month comparison
- Reworded:
- Older filing describes Physician LLCs consolidation as 'they do not have significant equity at risk, and we have historically provided support'; newer filing states 'they do not have significant equity at risk to finance their activities independently' with expanded explanation of primary beneficiary criteria
- Older filing describes primary beneficiary status more briefly; newer filing (2026-04-30) provides detailed two-part explanation: '(i) it has the power to direct the activities that most significantly affect their economic performance through its contractual and operational oversight, and (ii) it has the obligation to absorb losses and the right to receive benefits'
- Older filing describes Real Estate Entities consolidation without detail about related party control; newer filing (2026-04-30) explicitly states Real Estate VIEs 'are in part and, in some cases, controlled by related parties, including members of the Company's executive management team'
- Newer filing (2026-04-30) adds language about Physician LLCs being 'owned in part and, in some cases, controlled by related parties, including members of the Company's executive management team'
- Older filing's NSA description states 'to protect patients from surprise medical bills incurred when they receive emergency medical services'; newer filing expands to include 'as well as non-emergency services at in-network facilities, and air ambulance services'
- Older filing states 'scope of services provided in the facility'; newer filing states 'scope of services provided at the facility'
- Notes:
- Newer filing is for quarterly period ended March 31, 2026; older filing is for quarterly period ended September 30, 2025 (different reporting periods explain some operational metric changes)
- The comparison involves different fiscal periods which may naturally lead to changes in employee count, hospital facilities, and physician relationships
- Newer filing text appears truncated at end of 'Arbitration Awards Are Binding' section; older filing also appears truncated but at similar location
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days4 buys ($45705) · 0 sells — 4 buying insiders
Cluster buying: 4 different insiders reported open-market purchases (SEC code P) of NUTX within a 30-day window between 2026-03-13 and 2026-03-20. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-03-20. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NUTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding NUTX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 502,727
- Reported value $47,779,174
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NUTX had 1,104,332 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NUTX had 16.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.04 days to cover at the same settlement.
- Reported short interest (shares) 1,104,332
- Short interest (% of shares outstanding) 16.1%
- Prior settlement (shares) 1,049,917
- Reported change 5.18%
- Days to cover (reported) 9.04
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- United Health Group (UNH)
- CVS Health (CVS)
- Humana (HUM)
- Elevance Health (ELV)
- Amedisys (AMED)
- Encompass Health (EHC)
- Acadia Healthcare (ACHC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NUTX vs…
Frequently asked questions
What does NUTEX HEALTH INC (NUTX) do?
Nutex Health is a physician-led healthcare services company operating a network of 26 micro-hospitals, specialty hospitals, and hospital outpatient departments across 12 states, while also managing population health through independent physician associations and managed care networks. The hospital division provides comprehensive 24/7 care including emergency, inpatient, and behavioral health services with onsite ancillary services like imaging, labs, and pharmacies.
What sector is NUTEX HEALTH INC (NUTX) in?
NUTEX HEALTH INC (NUTX) is classified in the Health Care sector. Its industry is Micro-hospital operations and population health management. It trades on NASDAQ.
Does NUTX pay a dividend?
Yes — NUTEX HEALTH INC (NUTX) pays a dividend, with an indicated yield of about 6.32% (market data, as of 2026-08-24). Informational only — not financial advice.
Who are NUTEX HEALTH INC's (NUTX) competitors?
Notable peers of NUTEX HEALTH INC (NUTX) include United Health Group, CVS Health, Humana, Elevance Health and Amedisys. This peer set is informational only — not financial advice.
Is NUTEX HEALTH INC (NUTX) overbought or oversold right now?
NUTEX HEALTH INC (NUTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NUTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.